Scientific Program

Sunday, June 10, 2018

15:00-18:00 Registration
18:00-19:30

Opening session

Chair: Eitan Yefenof, Israel

Greetings

Opening lecture:Isaac Witz, Israel: The Tumor and its Environment: A Love-Hate relationship

19:30-21:00 Get together

 

Monday, June 11, 2018

08:30-10:30

Plenary session 1: Regulatory pathways at the Tumor Microenvironment

Auditorium I

Chair: Allan Lipton, USA

8:30

John Condeelis, USA: High resolution intravital imaging of tumor cell dissemination and seeding of distant sites in invasive carcinoma

9:00 Avraham Raz, USA: Galectin-3: A marker for understanding/improving bone tumor microenvironment management
9:30 Jonathan Sleeman, Germany: A new role for VEGF-C in metastatic conditioning of the lung
10:00 Luyuan Li, China: Oxygen-Independent Degradation of Hypoxia- Inducible Factor 1-Alpha
10:30-11:00 coffee break, Poster viewing
 
11:00-13:00

Plenary session 2: Targeting the Tumor Microenvironment

Auditorium I

Chair: Galina Shurin, USA

11:00 Alberto Mantovani, Italy: IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity
11:30 Yuval Shaked, Israel: Host mediated effects in response to anti-cancer drugs and their clinical implications
12:00 John Delinasios, Greece: Proliferating fibroblasts against cancer cells in vitro
12:30 TMaty Tzukerman, Israel: Shaping the soil for the seeds: Reciprocal reprogramming of cancer cells and associated Mesenchymal Stem Cells in gastric cancer
13:00- 14:00 Lunch
14:00

Special Guest Presentation

Auditorium I

Chair: Isaac Witz, Israel

Anna Dart, London, Associate Editor, Nature Reviews Cancer:

Publishing in nature research journals

 
14:30-16:30

Plenary session 3: Inflammation and the tumor microenvironment

Auditorium I

Chair Catherine Sautes-Fridman, France

14:30 Michal Banyiash, Israel: Myeloid derived suppressor cells in the tumor microenvironment
15:00 Adit Ben Baruch, Israel: Inflammation-driven networks in the regulation of breast cancer progression
15:30 Yves De Clerck, USA: Mesenchymal Stromal Cells: Mediators of Inflammation in Cancer
16:00 Ron Apte, Israel: Microenvironment IL-1beta as a major balance between tumor-promoting inflammation and anti-tumor immunity
16:30-17:00 Coffee break, Poster viewing
 
17:00-19:00

Plenary session 4: The Tumor Neuro-microenvironment

Auditorium I

Chair: Maria Rita Dionísio, Portugal

17:00 Bozena Kaminska, Poland: Identification and therapeutic targeting interactions between glioma and its microenvironment (sponsored by the EACR)
17:30 Michael Shurin, USA: The role of tumor-neural-immune axis at the tumor microenvironment
18:00 Christopher Gerner, Austria: From cutaneous metastasis to brain metastasis: proteome signatures and functional features of melanoma cells
18:30 Marcel Alexander Heinrich, The Netherlands: 3D Bioprinted mini-brains: a novel tool to study the interaction between Tumor-associated macrophages and cancer cells in glioblastoma multiforme
20:00 Conference dinner

 

 

Tuesday, June 12, 2018

08:30-10:30

Parallel sessions I

Session 5A

Regulatory pathways at the Tumor Microenvironment

Auditorium I

Chair: Zvi Granot, Israel

08:30

Rachel Bar-Shavit, Israel: Cancer driver G-protein coupled receptors; GPCRs: Molecular mechanism and translational means

08:45 Sandrina Nóbrega Pereira, Portugal: The Role of mitochondrial metabolism in breast cancer aggressiveness induced by hypercholesterolemia
09:00 Sofia C Nunes, Portugal: Enzymes involved in cysteine metabolism underlie hypoxia adaptation in ovarian cancer
09:15 Sofia Avnet, Italy: Acidosis and 3D interactions between tumor cells and mesenchymal stroma are crucial for profound cellular rewiring toward the regulation of lipid metabolism
09:30 Jesús Francisco Glaus Garzón, Switzerland: Gut microbiota-induced alterations of mucus glysosylation modulated cancer progression
09:45 Esther Priel, Israel: The interaction of bacteria with human tumor cells alters the activity of the cellular DNA topoisomerase I and the efficacy of anti-cancer drugs
10:00 Filipa Lopes-Coelho, Portugal: HNF1β, an oncogene-like protein, is stabilized by acetylation, preventing its ubiquitination and further degradation
10:15 Dalit Barkan, Israel: Soluble Mediators of Resolution-Promoting Macrophages Inhibit Breast Cancer Recurrence at the Metastatic Niche
 
Session 5B

The Metastatic Tumor Microenvironment

Auditorium lI

Chair: Bruno Costa-Silva, Portugal

08:30 Paulina Podszywalow-Bartnicka, Poland: Stress-induced signaling in chronic myeloid leukemia promotes cells invasiveness
08:45 Joana Carvalho, Portugal: Extracellular Vesicles: (fine) tuning the gastric cancer microenvironment
09:00 Zhe Liu Liu, China: Lymphocyte mimicry in epithelial cancer metastasis
09:15 Lee Shaashua, Israel: Micro-metastases regression following primary tumor excision: a critical role for primary tumor secretome
09:30 Tali Tavor Re'em, Israel: Constructing a dynamic three Dimensional in vitro model for investigation of ovarian carcinoma progression mechanisms
09:45 Reuven Reich, Israel: Role of S1P Signaling in ovarian carcinoma progression
10:00 Michael Grusch, Austria: Fibroblast growth factor-Induced EMT in malignant pleural mesothelioma aggressiveness
10:15 Zhi-Xiong Jim Xiao, China: Regulation of AMPK in cancer cell metabolism and tumor metastasis
 
Session 5C

Inflammation and Immunity at the Tumor Microenvironment

Auditorium III

Chair: Yaacov Ben-David, China

08:30 Imad Shams, Israel: New insights into cancer- and hypoxia-resistance in the blind mole rat, Spalax
08:45 Francesca Caccuri, Italy: U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis
09:00 Lukas Hawinkels, The Netherlands: Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis
09:15 Andrei Bakin, USA: A novel cellular crosstalk promoting tumor progression and metastasis
09:30 Chiara Polidoro, Italy: Lox-1 affects tumor growth and colon cancer neoangiogenesis acting by VEGF-A165
09:45 Nikolitsa Nomikou, UK: Exploiting the tumour microenvironment in order to optimise sonodynamic therapy for prostate cancer
10:00 Ana Paula Delgado, USA: Single cell RNA-Seq analysis of breast cancer progression
10:15 Catarina Brito, Portugal: 3D-3-culture: a tool to unveil tumour-macrophage crosstalk in the tumour microenvironment
 
10:30-11:00 Coffee break, Poster viewing
 
11:00-13:00

Parallel sessions II

Session 6A

Regulatory pathways at the Tumor Microenvironment

Auditorium I

Chair: Maria Jose Oliveira, Portugal

11:00 Jan A Burger, USA: The role of nurselike cells In the CLL microenvironment
11:15 Fares Qeadan, USA: P-value and its relationship to the effect size when modeling cytokines using the measure of stochastic superiority
11:30 Alba Herrero, Spain: Role of ICAM-1 and COX-2 in angiogenic and desmoplasic response by HSC recruitment
11:45 Allan Lipton, USA:Extracellular matrix (ECM) protein fragments in serum and outcomes in metastatic breast and pancreatic cancer patients
12:00 Michal Masarik, Czech Republic: Cell stiffness as a predictor of metastatic potential and therapy response in head and neck tumours
12:15 Sarah Ouahoud, The Netherlands: TRAIL produced by SMAD4 deficient tumors stimulates BMP2 production by fibroblasts and enhances colorectal cancer (CRC) invasiveness
12:30 Stefanie Kirchberger, Austria: Illuminating the tumor microenvironment in zebrafish cancer models
 
Session 6B

Inflammation and Immunity at the Tumor Microenvironment

Auditorium II

Chair: Adriana Haimovitz-Friedman, USA

11:00 Barbara Bottazzi, Italy: Migration Stimulating Factor, a new marker for M2-polarization affecting monocyte motility
11:15 Nuno Lopes, Portugal: Exploiting 3D Co-culture Models to Depict the Phenotype of Tumor Associated Macrophages in Breast Cancer
11:30 Maria José Oliveira, Portugal: Profiling macrophage populations in human colorectal cancer
11:45 Adi Karsch-Bluman, Israel: Effect of Necrosis on Cancer Resistance Mechanisms
12:00 Shimrit Avraham, Israel: Host ATF3 and JDP2 expression in the tumor microenvironment plays a dual role in carcinogenesis
12:15 Marta D. Kolba, Poland: Tunneling Nanotubes (TNTs) mediate bidirectional transfer of specific vesicular cargo and proteins between leukemia and stroma cells
12:30 Bin Shan, USA: Epigenetic activation of a novel isoform of lncRNA HOTAIR in lung and breast cancer cells attached to extracellular matrix
12:45 Raj Tiwari, USA: Tumor microenvironment of anaplastic thyroid cancer: Novel inflammatory and immunotherapeutic targets
 
Session 6C

Targeting the Tumor Microenvironment

Auditorium III

Chair: Michael Goldberg, USA

11:00 Reichle Albrecht, Germany: Anakoinosis: Reprogramming communicative networks in tumor systems, a review
11:15 Praneeth Reddy Kuninty, The Netherlands: Targeting integrin alpha 5 attenuates pancreatic tumor progression by abolishing tumor stroma
11:30 Kévin Louault, France: Interactions between cancer associated fibroblasts and tumor cells promotes MCL-1 dependency in luminal breast cancers
11:45 Silvia Laura Locatelli, Italy: Targeting the Hodgkin lymphoma tumor microenvironment through PI3K gδ inhibition
12:00 Deby Fajar Mardhian, The Netherlands: Relaxin-coated iron-oxide nanoparticles as a novel approach to inhibit tumor stroma in pancreatic tumor
12:15 Lina Ghibelli, Italy: Mechanisms of post-therapy tumor cell repopulations
12:30 Rajkumar Savai, Germany: Circulating fibrocytes plays a key role in lung tumor progression by modulating macrophage phenotype, angiogenesis and endothelin system
12:45 Zofia Pilch, Poland: Manipulation of CD200R signaling potentiates the anti-cancer effect of TLR7 agonist
 
13:00 Free afternoon

 

Wednesday, June 13, 2018

08:30-10:30

Parallel sessions III

Session 7A

Regulatory pathways in the Tumor Microenvironment

Auditorium I

Chair: Karine Serra, Portugal

08:30 Elena Bruni, Italy: NKp46 marks a novel Vd1-restricted gδT subset with potent anti-tumor activity resident in human intestinal mucosa
08:45 Sarah Baird, New Zealand: Cathepsin D enhances mesenchymal stem cell homing to tumour sites, where through production of tissue inhibitor of matrix metalloproteinases, they can reduce metastasis
09:00 Ruowen Ge, Singapore: Nucleolin is a novel cell-surface receptor for ADAMTS5 that mediates the antiangiogenic function of ADAMTS5
09:15 Ubaldo Soto, USA: Stem cell secreted factors induce changes in alpha-6 integrin splicing in skin melanoma and breast cancer cells leading to a less oncogenic phenotype
09:30 Sérgia Velho, Portugal: KRAS mediates colorectal cancer cell invasion induced by fibroblasts
09:45 Mahmoud Dabbah, Israel: CD49d expression on bone marrow mesenchymal stem cells’ microvesicles as a therapeutic target in multiple myeloma
10:00 Rinat Abramovitch, Israel: Elucidating the effects of chronic liver inflammation on colorectal cancer metastatic dissemination
10:15 Ada Rephaeli, Israel: Histone deacetylase inhibitory prodrugs of low molecular weight fatty acids AN7 and AN446 modify the tumor microenvironment
 
Session 7B

Inflammation and Immunity at the Tumor Microenvironment

Auditorium II

Chair: John Delinasios, Greece

08:30 Angela M Costa, Portugal: The hypoxia impact in the macrophage-driven cancer cell invasive phenotype
08:45 Marta Laranjeiro Pinto, Portugal: Unraveling the immunomodulatory role of colorectal cancer extracellular matrix on macrophage polarization
09:00 Michael Goldberg, USA: T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
09:15 Tali Feferman, Israel: Oxygen deprivation during T cell priming boosts tumor rejection in a mouse melanoma model
09:30 Charlotta Dabrosin, Sweden: Dense breast tissue and breast cancer in women exhibit similar pro-inflammatory microenvironment in vivo
09:45 Zvi Granot, Israel: The TRPM2 Ca2+ channel links EMT and tumor cell susceptibility and neutrophil cytotoxicity
10:00 Svetlana Miklikova, Slovakia: Breast cancer related changes of adipose tissue-derived mesenchymal stromal cells
10:15 Valeria Quaranta, UK: Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer
 
Session 7C

Targeting the Tumor Microenvironment

Auditorium III

Chair: Sandra Casimiro, Portugal

08:30 Milada Sirova, Czech Republic: Targeted modulation of tumor microenvironment using polymer drug delivery systems
08:45 Karine Serre, Portugal: Different TLR signalling pathways induce macrophages or neutrophils with anti-tumour functions in vivo
09:00 Fourniols Thibaut, Belgium: Targeting tumor associated fibroblasts with an antibody-grafted lipid nanocapsule
09:15 Marie-Ève Wedge, Belgium: Tailoring oncolytic viruses for the treatment of pancreatic cancer
09:30 Flávia Castro, Portugal: Reprogramming antigen-presenting cells: a chitosan/g-PGA nanoparticles for anticancer therapy
09:45 Avraham Dayan, Israel: RGD-modified Dihydrolypoamide Dehydrogenase Conjugated to TiO2 Nanoparticles – Application in Integrin-Targeted Photodynamic Treatment of Melanoma Cells
10:00 Mark Schoonderwoerd, The Netherlands: Synergistic inhibition of tumor growth by combined endoglin and anti-programmed cell death-1 (PD1) targeting in colorectal cancer
10:15 Adriana Haimovitz-Friedman, USA: Activation of anti-tumor immune response by partial-volume SINGLE dose radiation
 
10:30-11:00 Coffee break, Poster viewing
 
11:00-13:00

Parallel sessions IV

Session 8A

Inflammation and Immunity at the Tumor Microenvironment

Auditorium I

Chair: Reichle Albrecht, Germany

11:00 Wu-Min Deng, USA: The transitional region in epithelial tissues is hotspot for tumorigenesis
11:15 Ruth Scherz-Shouval, Israel:Stromal stress networks underlying phenotypic plasticity and tumor fitness
11:30 Yaacov Ben-David, China: Erythropoietin elicits a strong immune response against leukemic cells leading to tumor inhibition
11:45 Lazennec Gwendal, France: Involvement of chemokines in breast cancer aggressiveness
12:00 Dominika Piasecka, Polland:Inflammatory stimuli promote growth of HER-2 negative non-invasive mammary epithelial cells
12:15 Carles Urbiola, Austria: Tumor Cytokine Profile in Oncolytic Virotherapy of Solid Tumors with VSV-GP
12:30 Lubor Borsig, Switzerland:Chemokine-induced vascular permeability promotes lung metastasis
12:45 Valentin Baloche, France:Contribution of galectin-9 to tumor immune escape: basic and pre-clinical investigations in the CT26 murine tumor model
 
Session 8B

Cellular and Molecular interactions at the Tumor Microenvironment

Auditorium II

Chair: Sergio Dias, Portugal

11:00 Bettina Couderc, France:Mesenchymal stromal cells are involved in chemoresistance and macrophages polarization through the CXCR1/2 ligands’s release
11:15 Sofia Mensurado, Portugal:Tumor-associated neutrophils suppress pro-tumoral IL-17+ gδT cells through induction of oxidative stress
11:30 Victoria Jennings, UK:Enhancing oncolytic virotherapy by exosome-mediated microRNA reprograming of the tumour microenvironment
11:45 Marcello Ehrlich,Israel: Manipulation of the Tumor Microenvironment through a Three-Way Molecular Tug-of-War: Oncogenic Signaling, Innate Immune Anti-Viral Responses and Viral Oncolysis
12:00 Ismael Sánchez-González, Germany:miR-149 functions as a tumor suppressor by controlling invasive motility through both cell intrinsic and paracrine signaling mechanisms
12:15 Azzarone Bruno, France: Interleukin 15 is a major player in renal cancer progression
12:30 Reuven Stein, Israel: Targeting CD38 in the tumor microenvironment inhibits progression of primary melanoma and generation of spontaneous metastasis
12:45 Raya Leibowitz-Amit, Israel: Immune checkpoint and micro-RNA networks at the tumor side of the immunological synapse in cancer – implications for immunotherapy
 
Session 8C

Preclinical and Clinical Trials

Auditorium III

Chair: Jose Carlos Machado, Portugal

11:00 Anette Hauge, Norway: Exploring the Tumor Microenvironment with Functional Magnetic Resonance Imaging
11:15 Soraia Lobo de Martins, Portugal: Neutrophil to lymphocyte ratio (NLR) as a predictor of overall survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with Radium-223
11:30

Tommaso Cavalleri, Italy: Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes for the intra-stage II identification of colorectal cancers with the highest risk of progression

11:45 Filipa G. Marques, Portugal:Neovascularization is induced in human peritumoral tissues after radiotherapy
12:00 Sandra Casimiro, Portugal: Prognostic role of secreted YB-1 in patients with breast cancer
12:15 Lutz Menzel, Germany: Remodeling of the lymph node vascular environment in aggressive B cell lymphoma involves distinct morphologies and signaling pathways
 
13:00-14:00 Lunch
 
14:00-14:30

Business Meeting

Auditorium I

 
14:30-16:30

Plenary session 9: The Metastatic Microenvironment

Auditorium I

Chair: Bozena Kaminska, Poland

14:30 Achim Krueger, Germany: Nomen non est omen: Pro-metastatic signaling functions of tissue inhibitor of metalloproteinases-1 (TIMP-1)
15:00 Arne Ostman, Sweden: , Prognostic and response-predictive potential marker-defined tumor-stroma cell subsets
15:30 Menashe Bar-Eli, USA: A-to-I micro RNA editing and melanoma metástases
16:00 Heike Allgayer,, Germany: The genomic landscape characterizing metastasis
 
16:30-17:00 Coffee break, Poster viewing
 
17:00-19:00

Plenary session 10: The immune-microenvironment of Cancer

Auditorium I

Chair: Bernd Groner, Switzerland

17:00 Wolf Fridman, France: Cancer and micro-environmental factors that tune T cell responses
17:30 Shimon Sakaguchi, Japan: Targeting regulatory The cells in tumor microenvironment
18:00 Ofer Mandelboim, Israel: Cancer associated bacteria protect the tumor from immune cell attack
18:30 Chatherine Sautes- Fridman, France: Tertiary lymphoid structures in cancer: friends or foes?

 

Thursday, June 14, 2018

08:30-10:30

Plenary session 11: Clinical aspects of Tumor Microenvironment Research

Auditorium I

Chair: Heike Allgayer, Germany

8:30 Luis Costa, Portugal: Targeting the microenvironment of solid tumors: Clinical achievements and challenges
9:00 Yona Keisari, Israel: Elimination of human and mouse solid malignant tumors by intra-tumoral Ra-224 loaded sources in combination with systemic chemotherapy and immunotherapy
9:30 Emiliano Calvo, Spain: Why are there no advances in the therapy of pancreatic cancer?
10:00 Jai Prakash, The Netherlands: A novel integrin alpha5 binding peptide for tumor stroma imaging and potentiating the effects of chemotherapy in pancreatic cancer
 
10:30-11:00 Coffee break
 
11:00

Closing session

Auditorium I

Poster Session – Presentation of Best Posters and Awarding of Prizes

Eitan Yefenof, Israel: Summary and Outlook

12:00 Adjourn